Vyuhpharma

Highlights from the week of
4th May - 11th May

Lannett

(FDA, Approval)

FDA approves Lanex Biologics' subsidiary Lannett and Sunshine Lake Pharma's interchangeable biosimilar, LANGLARA, to treat adult and pediatric patients with type 1 diabetes mellitus and adults with type 2 diabetes mellitus

---

Bristol Myers Squibb

(EU, Approval)

EC grants approval to Bristol Myers Squibb's SOTYKTU, a once-daily, oral, selective TYK2 inhibitor to treat active PsA in adults with inadequate or intolerant response to DMARD therapy

---

Biocon

(Health Canada, Approval)

Biocon gets Health Canada approval for its micafungin injection, USP, 50 mg and 100 mg for the treatment and as a prophylaxis of various Candida infections in patients undergoing hematopoietic stem cell transplantation

---

Merck

(Acquisition)

Merck acquires Terns Pharmaceuticals along with its Breakthrough Therapy Designation drug TERN-701, a potential treatment option for certain patients with chronic myeloid leukemia

Vyuhpharma

Highlights from the week of
4th May - 11th May

Roche *(Acquisition)*

Roche and PathAI enter into a merger agreement to strengthen Roche's digital pathology facilitating faster diagnostic workflows

---

Hikma *(Partnership)*

Hikma and Marius agreed to commercialize and distribute KYZATREX CIII capsules in Canada, indicated for testesterone replacement therapy

---

Neuland *(Collaboration)*

Neuland partners with LIR Life Sciences Corp to manufacture CPPs supporting PK, PD studies and Phase 1 formulations for LIR Life's transdermal GLP-1/GIP program targeting obesity

---

Halozyme *(Collaboration)*

Halozyme and GSK enter into a global collaboration and license agreement to develop and commercialize multiple subcutaneous oncology targets including ADCs through Halozyme's ENHANZE drug delivery technology

Vyuhpharma

Highlights from the week of
4th May - 11th May

UCB *(Partnership)*

UCB collaborates with Cancer Research UK and its arm, Cancer Research Horizons, to progress its development pipeline of novel oncology candidates

Johnson&Johnson *(Phase 3, Results)*

Johnson & Johnson's FUZION study evaluating TREMFYA in adults with active perianal fistulizing CD demonstrates higher combined fistula remission rates at Week 24 with stringent endpoints compared to placebo

Moderna *(Phase 3, Results)*

Moderna's Phase 3 study evaluating mRNA-1010 achieves rVE 26.6% in the overall study population with each infulenza strain containing the vaccine, confirming strong rVE estimates in subgroup analyses

Takeda *(Phase 3, Results)*

Takeda's pivotal Phase 2/3 trial demonstrates comparable PK and safety profiles in TAK-881 to HYQVIA, providing immune protection in PID, and meeting its primary endpoint with no new safety signals